11/06/2025
We’re proud to congratulate Dr. Bhupendra Khatri, Anna Cluskey, PA-C, Scott Schutten, APN, Pamela Van Zeeland, RN, Sergey Tarima, PhD, and Toni Perea, RN on their recent publication in Multiple Sclerosis Journal – Experimental, Translational and Clinical (2025): A recent single-center, real-world study followed 238 patients treated with Ocrelizumab for up to 5.9 years to assess the relationship between B-cell depletion, immunoglobulin levels, and infection risk.
As a neurology practice focused on MS and neuroimmunology, we’re committed to integrating evidence like this into real-world care decisions — ensuring our patients benefit from disease-modifying therapies while maintaining immune safety through proactive monitoring.
Source: Sage Publications – Multiple Sclerosis Journal – Experimental, Translational and Clinical (2025)
https://doi.org/10.1177/20552173251391975